series-a
Stage
2018
Founded
About
Aurum Biosciences is a clinical stage biopharmaceutical company focused on developing therapeutics and diagnostics for unmet clinical needs, primarily using oxygen carriers and proprietary MRI software. Its lead product, ABL-101, targets acute ischemic stroke and spinal cord injury, with potential applications in inflammation, oncology, and cardiovascular conditions.
Explore Aurum Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.